Metabolic and hemodynamic effects of pioglitazone in obese patients with type 2 diabetes

The purpose of the study was to evaluate the effectiveness and safety of pioglitazon, a hypoglycemizing preparation belonging to the group of thiazolidinediones, in treatment of diabetes mellitus (DM) type 2. Twenty DM type 2 patients were included in the study. The use of pioglitazon during 12 week...

Full description

Saved in:

Bibliographic Details
Published in:	Klinicheskaia meditsina Vol. 84; no. 10; p. 44
Main Authors:	Demidova, T Iu, Ametov, A S, Titova, O I
Format:	Journal Article
Language:	Russian
Published:	Russia (Federation) 2006
Subjects:	Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Female Humans Hypoglycemic Agents - therapeutic use Insulin Resistance - physiology Intra-Abdominal Fat - metabolism Male Middle Aged Thiazolidinediones - therapeutic use
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The purpose of the study was to evaluate the effectiveness and safety of pioglitazon, a hypoglycemizing preparation belonging to the group of thiazolidinediones, in treatment of diabetes mellitus (DM) type 2. Twenty DM type 2 patients were included in the study. The use of pioglitazon during 12 weeks resulted in a significant decrease in glycated hemoglobin, fasting glycemia, and postprandial reduction in insulinemia and insulinoresistance index HOMA-IR, as well as an improvement of lipid blood spectrum and the lessening of visceral obesity. Besides, a positive effect on arterial pressure was noted. The study revealed no significant adverse effects; good tolerance to treatment was noted in 90% of the patients.
ISSN:	0023-2149